Neptune Secures and Increases US Food, Drug, Mass and Club Distribution
June 22 2011 - 8:30AM
Neptune Technologies & Bioressources Inc. (Neptune)
(Nasdaq:NEPT) (TSX-V:NTB) announces that it is significantly
enhancing its presence in the US Food, Drug, Mass and Clubs Sales
Channels.
Neptune has recently finalized agreements with two major US
distributors to sell Neptune Krill Oil through their well
established network of US national retailers and wholesalers. This
important development in the mass market will once more place
Neptune as an industry leader in the overall krill oil market.
"This constitutes a major accomplishment in significantly
increasing Neptune's share of the Omega-3 market," stated André
Godin, CFO. "We now have even more influential partners with clear
vision and extensive resources to build strong brand recognition
amongst the largest retailers," Mr. Godin added.
These agreements involve yet another organization, B&D
Nutritional Ingredients, which has been a leader in the dietary
supplement industry since 1993 and offers a portfolio of products
from leading global manufacturers. "As an ingredient supplier in
the US market, we wanted to be associated to the best krill oil
manufacturer available with exceptional scientific credential,
there was no other partner comparable to Neptune," said Bill Van
Dyke, CEO of B&D Nutritional Ingredients and former Chairman of
the US Council of Responsible Nutrition. "The two distributors
which cumulate over 70 years of industry expertise are known for
being both strong brand promoters and innovators in various
categories of supplements that are substantiated with proven
science. The two distributors represent together close to 30% of
the US mass market nutraceutical business, accessing more than
100,000,000 Americans with nationwide market coverage in over
54,000 retailers. Following initial commitments from these large
distributors, we estimate a minimum volume of 50,000 kg per year,"
he concluded. Neptune currently produces 130,000 kg annually.
This important incremental US market presence is consistent with
Neptune's overall business strategy of sustained revenue growth in
the nutraceutical business. The increased demand generated by the
two new distributors is also in line with the plant capacity
expansion which will commence shortly. The new state of the art
plant add on will more than double the existing capacity and not
affect the current production. "The Plant capacity increase will
shortly contribute to sustain the continuous strong growth of
Neptune," noted Frederic Harland, Finance Director of Neptune. "It
is very important to also underline that the expansion will be done
without a plant shutdown," Mr. Harland added.
Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release."
Statements in this press release that are not
statements of historical or current fact constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known and unknown
risks, uncertainties, and other unknown factors that could cause
the actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged
to consider statements labeled with the terms "believes," "belief,"
"expects," "intends," "anticipates," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company's
reports filed with the Securities and Exchange Commission and the
Canadian securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group Contact:
Bob Beaty
(888) 221-0915
bob@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024